Company profile for GamaMabs Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

GamaMabs is a privately held immuno-oncology biotechnology company specialized in the development of optimized monoclonal antibodies (mAb). Its lead program is GM102 (formerly 3C23K), a mAb targeting the receptor of the anti-Müllerian hormone (AMHR2) in gynecological cancers, currently in phase Ia/Ib stage. GM102 has increased tumor cell killing properties through the activation of immune system cells, thanks to its EMABling...
GamaMabs is a privately held immuno-oncology biotechnology company specialized in the development of optimized monoclonal antibodies (mAb). Its lead program is GM102 (formerly 3C23K), a mAb targeting the receptor of the anti-Müllerian hormone (AMHR2) in gynecological cancers, currently in phase Ia/Ib stage. GM102 has increased tumor cell killing properties through the activation of immune system cells, thanks to its EMABling® glyco-engineering technology. Founded in June 2013 in Toulouse (France), GamaMabs employs 7 professionals with a sound and successful experience in preclinical and clinical development up to registration.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
Centre Pierre Potier 1 place Pierre Potier ONCOPOLE entrée B BP 50624 –...
Telephone
Telephone
+33 (0)5 31 61 60 69
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty